Last update Dec. 20, 2022

Indinavir Sulfate

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

It is an HIV protease inhibitor with antiviral activity against HIV. It is used in the treatment of HIV infection and AIDS. Administration together with other oral antiretrovirals in three daily doses.

It is excreted in breast milk in unknown concentration, but between one and five times higher than plasma. (Colebunders 2005)

The most frequent side effects are gastrointestinal disorders (abdominal pain, diarrhea, nausea and vomiting), headache, dizziness and nephrolithiasis and renal failure.

During lactation other HIV/AIDS treatments are preferable. (Panel 2022, WHO 2016)


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Indinavir Sulfate in other languages or writings:

Group

Indinavir Sulfate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Indinavir Sulfate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 30 - 65 %
Molecular weight 712 daltons
Protein Binding 61 %
pKa 13.01 -
Tmax 0.8 (0.5 - 1.1) hours
T½ 1.8 (1.4 - 2.2) hours
M/P ratio 0.9 - 5 -

References

  1. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2024 Abstract Full text (link to original source)
  2. WHO - World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Guideline. 2016 Abstract Full text (link to original source) Full text (in our servers)
  3. CDC - Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States. nPEP Guidelines Update. 2016 Full text (link to original source) Full text (in our servers)
  4. Colebunders R, Hodossy B, Burger D, Daems T, Roelens K, Coppens M, Van Bulck B, Jacquemyn Y, Van Wijngaerden E, Fransen K. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS. 2005 Nov 4;19(16):1912-5. Abstract Full text (link to original source)

Total visits

3,486

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM